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With great interest we read the recent paper in Mediators of
Inflammation byThomas Stu¨big and colleagues [1] as the aim
of this study was similar to the aim of a study we recently con-
ducted [2], namely, to study the impact of the demethylating
agent 5-Azacytidine on the immune system.The two studies,
however, reached different conclusions, which as we will
discuss below may originate from differences in the patient
cohorts and the translation of data from in vitro analyses
into in vivo effect. Thus, with the present commentary we
would like to discuss the challenges in understanding the
true effect of 5-Azacitidine on immune reactivity in cancer
patients and how this may depend on the patient group
analyzed. 5-Azacytidine was marketed (as Vidaza, Celgene
Corporation, Boudry, Switzerland) after a phase III trial
revealed it as the first drug prolonging overall survival in
high-risk myelodysplastic syndrome (MDS) patients [3]. 5-
Azacytidine is known to upregulate the expression of tumor
suppressor genes [4], and it has been speculated to what
extent it impacts the immune system, both directly and
indirectly.
Stu¨big and coworkers analyzed the blood from healthy
donors subjected to in vitro stimulation with 5-Azacytidine.
They showed 5-Azacytidine-mediated inhibition of CD8
growth and killing capacity against a leukemic cell line,
induction of CD4 regulatory T cells, reduction in proinflam-
matory Th1 cells, a shift in phenotype from memory to naı¨ve
for CD4 and CD8 T cells, and overexpression of the cell
cycle inhibitor p15—in essence an inhibition of antileukemic
immunity. These findings are interesting, but it should be
noted that all analyses were done in vitro using blood from
healthy donors and, moreover, all of these were performed
with 5 or 20𝜇M 5-Azacytidine. Conclusions related to the
actual in vivo effect in cancer patients should be carefully
drawn. We conducted ex vivo analyses using blood from
a group of higher risk MDS and acute myeloid leukemia
(AML) patients and did not detect the significant immune
modulatory effects as observed by Stu¨big and coworkers in
vitro. We obtained blood samples from seventeen patients
diagnosed withMDS or AML before and after treatment with
5-Azacytidine at several time points for ex vivo investigation.
We isolated CD8 T cells and CD34 myeloid blast cells (as a
surrogate marker for the tumor cells) and were able to show
that 5-Azacytidine treatment increased the T-cell mediated
recognition of these by directly affecting the tumor cells,
while the CD8 T cells were not affected.This effect may relate
to 5-Azacytidine-mediated upregulation of cancer-testis anti-
gens and/or MHC class I molecules, as has been described
[4–7]. We were not able to correlate this directly due to a
limited amount of cell material, but we also screened for a
broad range of CD8 T-cell populations specific for cancer-
testis antigens with MHC multimers and found a significant
increase in the proportion of T cells recognizing these upon
initiation of treatment. Further, we investigated the absolute
numbers of the general populations of CD4 and CD8 T cells,
regulatory CD4 T cells, and myeloid-derived suppressor cells
and found no significant differences upon treatment with 5-
Azacytidine, when comparing the level prior to treatment
and at a late sample obtained at 4th–6th cycle. Expression
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of the regulatory T-cell marker FOXP3 has previously been
shown to be strongly regulated by methylation in vitro [8]
and in vivo in a transplantation setting [9], but the treatment
did not increase the regulatory T-cell population in absolute
numbers in our patients.
Thus, there seems to be a discrepancy between the in
vitro assessments and the in vivo effect and further between
different patient groups in vivo. Clinically the drug reaches
a peak concentration of around 3 𝜇M when patients are
treated subcutaneously with 75mg/m2 [10] and is expected
to reach 4 𝜇M upon in vivo treatment with 100mg/m2 as
was the dose used in both in vivo studies discussed here.
The use of 5 𝜇M as the lowest concentration in vitro thus
represents a 25% overdose while 20 𝜇M is out of range
compared to the treatment level. Others have previously
investigated the effect of 5-Azacytidine in vitro on the Natural
Killer (NK) cells and found that 5-Azacytidine impairs NK
cell reactivity in vitro [11, 12]. We confirmed this finding
after 5-Azacytidine exposure at 2.5 and 5.0 𝜇M. The effect
was, however, not as evident in vivo and we only noted a
trend towards a decrease in the absolute numbers of NK
cells along with a small, although significant, increase in NK
cells with an inhibitory phenotype. Further, we found the
in vitro impairment to be concentration-dependent, as we
also conducted the experiment with the calculated 8-hour
physiological concentration on 0.88 nM [10] and found no
inhibition of NK cell reactivity. It is not known what factors
differing between the in vitro and in vivo situations that are
responsible for these differences, but our data indicates that
the immunological effect of 5-Azacytidine is very sensitive
to concentration changes and that in vitro analyses even at
the physiological relevant concentration are not necessarily
relevant for the in vivo situation.
Furthermore, the in vivo immune modulatory effect of
5-Azacytidine may vary depending on the patient group
studied. Stu¨big and colleagues analyzed the in vivo effect of 5-
Azacytidine treatment in three patients after allogeneic stem
cell transplantation (alloSCT) and observed a tendency for
immunemodulation comparable to their in vitro studies, that
is, less CD8 and more CD4 cells, a decrease in activated
CD3+HLA-DR+ cells, and a shift from memory to na¨ıve
CD4 and CD8 T cells. The development of regulatory T
cells was more dynamic but seemed to increase and this is
in line with the previous data on 5-Azacytidine treatment
upon alloSCT in a larger patient group [9]. These alloSCT
patients were lymphodepleted and treated in a setting of
ongoing immune reconstitution (at 66, 96, and 127 days
after transplantation, resp.). Reconstitution of the innate
immune cells, for example, the NK cells following alloSCT,
is quite fast, but the adaptive immune cell populations are
delayed, and the T cells are not fully reconstituted until years
after the depletion (as reviewed in [13]). Thus it may be
speculated that the immune cells under these circumstances
aremore susceptible to epigeneticmanipulation than patients
that are not lymphodepleted. In addition, 5-Azacytidine was
administered in this situation to treat relapse or minimal
residual disease after the transplantation, while the patients
we treated had a heavy disease burden. Thus there seems to
be a difference in the immunemodulation sensitivity between
these two patient groups (alloSCT-treated MDS patients ver-
sus higher risk MDS and AML patients).Therefore, the effect
mediated by 5-Azacytidine should be carefully monitored
in the patient group of interest prior to the design of an
immune modulating therapeutic intervention. Responses to
5-Azacytidine are often delayed (e.g., [3]) and it has been
established that immune modulators often have a slower
onset than cytotoxic drugs [14]. We hence decided to use
samples obtained from 4th to 6th cycle of treatment as
the earliest endpoint; for part of our investigations we even
extended the analyses to the blood sample obtained after
10th cycle to be able to measure the long-term effects of
treatment. Stu¨big and coworkers, on the contrary, exclusively
used samples obtained after the initial treatment cycles, which
may reveal a different response profile.
With these reflections we hope to have convinced you
that the immune modulatory effects of treatment with 5-
Azacytidine are complex and dependent on the clinical
setting. Hence, it seems that in vitro measurements of this
treatment are suboptimal and should be carefully assessed in
the patient group of interest, as different patient groups may
respond differently to the epigenetic modulation conceived
by 5-Azacytidine.
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